🇺🇸 FDA

Company profile · Sponsor

Eisai

Eisai GmbH

EA8BD73 · EMA pharma EU
Pipeline
7
Drugs
0
Patents
0

Quick answer

Eisai (EA8BD73) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EA8BD73
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (7)

Search pipeline →

  1. LECANEMAB

    Eisai

    Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid

    phase 3 small molecule active

    1 trial

  2. Lecanemab

    Eisai

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial

  3. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  4. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  5. Fycompa 2 mg film-coated tablets, Fycompa 2 mg film-coated tablets, Fycompa 0.5 mg/ml oral suspension, Fycompa 2 mg film-coated tablets

    Eisai

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial

  6. LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

    Eisai

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  7. farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Eisai

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Eisai?

Eisai (EA8BD73) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Eisai sponsor?

We track 7 ClinicalTrials.gov-linked programs for Eisai, including LECANEMAB and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Eisai company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.